EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).

CMN-005 is under clinical development by Benecyte and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition ...

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

Oxford Gene Technology has announced the launch of its newly updated NGS SureSeq™ CLL + CNV V3 Panel. This new panel was ...

The global leukemia therapeutics treatment market has seen considerable growth, progressing from USD 14,504.8 million in 2022 to USD 15,246.7 million in 2023. With a projected compound annual growth ...

Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia Sep. 17, 2024 — According to new research, 80% of patients with previously untreated or relapsed/refractory ...

Discover how exercise enhances cancer treatment outcomes, supported by new scientific research showing promising results for ...

As I prepare for treatment of my chronic lymphocytic leukemia, I reflect on the challenges of aging and side effects while ...

Takeda-backed Ascentage Pharma (AAPG), which is developing drugs to treat blood cancers, has filed to raise up to $100M through a U.S. initial public offering. Read more here.

In separate, live virtual events, Alvaro Jose Alencar, MD, and Michael E. Williams, MD, discussed third-line options for a patient with relapsed/refractory chronic lymphocytic leukemia (CLL).

INR:7873. kerala lottery result chart 2010 Why is Internet medical care different inside and outside hospitals? A spray in the nose could provide ...

Practice-changing studies in both frontline CLL and relapsed/refractory disease, presented at ASH 2024, are discussed by Dr Jennifer Woyach.